Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)

Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)

Background POD1UM-201, an open-label, single-arm, phase II multiregional study, evaluated efficacy and tolerability of retifanlimab, a humanized monoclonal antibody targeting programmed cell death protein-1 (PD-1) in chemotherapy-naive patients with recurrent locally advanced or metastatic Merkel ce...

Full description

Saved in:
Bibliographic Details
Main Authors: Federica Morano, Celeste Lebbe, Mark Cornfeld, Shailender Bhatia, Melissa Burgess, Giovanni Grignani, Piotr Rutkowski, Francesca Spada, Michele Guida, Chuan Tian, Caroline Gaudy-Marqueste, Roberta Depenni, Henri Montaudié, Jennifer Pulini, Francesco Spagnolo, Cecilia C S Yeung
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/8/e012478.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/8/e012478.full

Similar Items